![BeardBros_BlogImages [Recovered]](https://beardbrospharms.com/wp-content/uploads/2026/07/BeardBros_BlogImages-Recovered-scaled.png)
I recently had the opportunity to attend and speak at the IgniteIt Cannabis Capital Conference in Chicago, where much of the conversation centered around what comes next for cannabis, capital, and healthcare.
It was encouraging to be in a room where people were taking seriously the question of how cannabinoid products may fit into the broader healthcare system. These are conversations that many of us have been having for years, but the recent CMS CBD pilot program has brought a new level of attention to the issue.
What the CMS CBD Pilot Program Actually Is, and What It Isn’t
The CMS pilot is historic, but it is not simple. It is not a blanket Medicare benefit, and it is not a reimbursement program where a Medicare patient can purchase a CBD product and submit a claim. Under the Substance Access Beneficiary Engagement Incentive (BEI), eligible participating healthcare organizations may furnish eligible hemp-derived products to eligible beneficiaries, up to a certain annual amount, within specific CMS Innovation Center models and under clinician guidance.
That distinction matters because it changes the way this program has to be understood and implemented.
As of today, to my knowledge, no Medicare patient has yet obtained a covered CBD product from their physician under this pilot program. That surprises people, and I understand why. When a federal program is announced, especially one involving CMS and cannabinoid access, there can be an assumption that the pathway is already functioning in practice. But there is a difference between a policy pathway existing and a healthcare organization being ready to operationalize it.
What Physicians and Healthcare Organizations Need to Implement CBD Access Under Medicare
For a physician or healthcare organization to participate, there are real questions that have to be answered. Which products are eligible? Who is responsible for purchasing and supplying them? How will dosing be discussed? How will medication interactions be reviewed? How will patient goals be documented? What follow-up is required? What happens if a patient is already using a cannabinoid product from a company they trust? How does the practice explain this program without creating confusion around reimbursement or access?
These are not small details. They are the infrastructure that determines whether a program like this can become meaningful for patients.
What 13 Years of Cannabinoid Research Reveals About Patient Needs
At Realm of Caring, we have spent more than 13 years working with patients and families who are seeking information about cannabinoid therapies. We have also worked alongside researchers, healthcare providers, product companies, and advocates to better understand what people are using, why they are using it, and what outcomes they are experiencing.
One of the lessons I have learned is that patients are often ahead of the systems that are meant to serve them. They are already using products and asking questions. They are also weighing risks and benefits, sometimes with very little support from their healthcare team.
This does not mean every product is appropriate for every patient, nor does it mean cannabinoids should be discussed without caution. It means that silence has not stopped use and has only made it harder for patients and providers to have informed conversations.
If cannabinoid care is going to be integrated into healthcare, physicians need more than a headline about a CMS pilot. They need practical, balanced education. They need summaries of existing research. They need to understand potential drug interactions, product quality considerations, appropriate patient conversations, and how to document shared decision-making. They also need to feel that they can ask questions without being sold to or expected to become cannabinoid experts overnight.
The Cannabis Industry’s Responsibility in Building a Credible Hemp-Derived CBD Healthcare Framework
The cannabis industry has a responsibility here as well.
For years, patients have been learning about cannabinoid products from dispensaries, product websites, social media, peer groups, and nonprofit organizations like Realm of Caring. Some of that education has been incredibly helpful, and some has been incomplete or overly confident. If we want healthcare to take cannabinoids seriously, we have to be willing to meet healthcare with the level of responsibility it requires. That includes supporting research, not just referencing it when it is convenient.
Product companies that want to be part of healthcare conversations should be willing to encourage their customers to participate in observational research and report outcomes over time. They should be open to independent review, transparent about product testing, and committed to helping build evidence rather than relying only on marketing language.
CBD Product Quality, Patient Choice, and the Standards That Support Informed Access
This is especially important because the CMS pilot should not become a narrow conversation about which products get in first. Product quality and safety matter, but patient choice matters too. Patients respond differently to different products, cannabinoid ratios, formulations, and dosing approaches. A responsible pathway should create standards without eliminating meaningful choice.
Patients did not begin using CBD in 2026. Physicians did not begin hearing about cannabinoid use because CMS announced a pilot. There is already a significant amount of real-world experience, observational research, patient-reported outcomes, and product use data that should help inform this next phase.
At Realm of Caring, our independent research studies and participation in broader research efforts, including work with the NIH-funded Cannabis and Health Research Initiative, are built around this exact need. We need to better understand how people are using cannabinoids in everyday life, what outcomes they are reporting, what safety considerations are emerging, and how that information can support patients, providers, researchers, and policymakers.
If we do not collect data during this pilot period, we will miss one of the most important opportunities this program offers.
Building the Infrastructure for Informed Cannabinoid Access: What Comes Next
The goal should not only be access, but informed access. That means patients have options, physicians have education, healthcare organizations have implementation support, product companies have accountability, and policymakers have data that reflects real-world use.
This will require relationship building in a way the cannabis industry is not always used to because healthcare is not going to move at the speed of cannabis. Physicians and healthcare administrators are managing liability, compliance, documentation, patient safety, payer rules, and clinical workflow. If we want them to engage, we have to understand those pressures and help solve for them.
That means bringing product companies, patients, physicians, researchers, and healthcare organizations into the same conversation. Not after decisions have already been made, but during the process of building the systems that will affect patient access.
The CMS CBD pilot is a meaningful step. It signals that cannabinoid therapies are being considered from the highest levels of our healthcare system in a way we have not seen before. But the announcement itself is not the finish line.
The work ahead is practical. It is education, implementation, product review, physician engagement, patient communication, research participation, and follow-up. It is making sure that the people this program is meant to serve are not lost in the complexity of the program itself.
I left Chicago encouraged because the conversation is moving. I was also left reminded that we have to be disciplined about what comes next.
If we want cannabinoids to have a legitimate place in healthcare, we have to do more than celebrate a federal pilot program. We have to build the relationships, evidence, and infrastructure that allow it to work for patients.
Frequently Asked Questions
Starting April 1, 2026, Medicare beneficiaries can receive up to $500 worth of FDA-approved CBD products per year through the CMS Substance Access Beneficiary Engagement Incentive (BEI) program. Participating healthcare organizations can provide these hemp-derived products under physician supervision within specific Medicare models.
Medicare does not directly reimburse patients for CBD. Instead, approved providers supply these products at their own expense under a specific CMS pilot program, rather than as a standard Medicare benefit.
To be eligible, you must be a Medicare beneficiary aligned with an approved ACO REACH, Enhancing Oncology, or LEAD Model participant. You must also be at least 18 years old, meet frailty requirements, have no disqualifying conditions, and not be pregnant or breastfeeding.
To be eligible, products must contain no more than 0.3% delta-9 THC and follow all state and local laws. Inhalable products and those with more than 3mg of THC per serving are not eligible, nor are products containing synthetic or non-natural cannabinoids.
Real-world patient data and research from organizations like Realm of Caring are key to developing effective cannabinoid healthcare policies. Collecting strong evidence during pilot programs will help improve patient outcomes and build physician trust in cannabis medicine.
To establish long-term credibility in healthcare, cannabis companies must move beyond marketing and commit to rigorous standards, including clinical research, transparent testing, and independent reviews.
Having dedicated 13 years to nonprofit work, Sasha Kalcheff-Korn has focused her career on improving the well-being of others through education, advocacy, and research. As the Executive Director of Realm of Caring, she leads efforts to advance cannabis research, break stigmas through education, and empower individuals and families to take control of their health.
Realm of Caring’s science-backed approach has impacted over 100,000 lives worldwide, particularly those living with chronic conditions. The organization plays a pivotal role in cannabis research, publishing data from its Observational Research Registry, the largest prospective epidemiological survey of cannabinoid users in the U.S. Since its founding in 2013, Realm of Caring has gained invaluable insights through IRB-approved studies and its free call center, examining the long-term effects of cannabinoid therapy.
A passionate advocate for informed patient choice and policy reform, Sasha regularly speaks at conferences and leads discussions on the intersection of cannabis, healthcare, and research. She values bridging scientific data with real-world impact to ensure that evidence-based cannabis solutions reach those who need them most.
